You have to admire Pharmacyclics advertising capability. Here they are showing how effective Ibrutinib (Imbruvica) is on a tough to treat bunch of CLL patients. "These patients had a median of five prior therapies and 63% were high-risk del 17p CLL patients. The estimated median progression-free survival (PFS) at 24 months was 76.6%. All patients had previously undergone allogeneic stem cell transplants."
Photo: Some red eucalyptus blossoms